How to Outsource Regulatory Submission Management

A Practical Guide for Early-Stage Pharma and Biotech

For small and early-stage pharmaceutical and biotechnology companies approaching their first IND or scaling toward a major filing, outsourcing regulatory submission management can be an important part of the strategy. This guide walks you through exactly how to do it.

Outsourcing Regulatory Submission Management as an Operational Strategy

There’s a common assumption in early-stage pharma and biotech that outsourcing is what you do when you can’t afford to hire. It’s the backup plan or stopgap.

That assumption can cost companies time, money, and clean submission records.

The most operationally sophisticated early-stage teams outsource regulatory submission management by design, before their first IND sequence is ever assembled. Not because they lack resources, but because they understand something fundamental: regulatory publishing and submission management is a specialized technical discipline with its own tools, standards, and institutional knowledge. It is not something a regulatory affairs lead picks up in their spare time between authoring summaries and reviewing clinical study report (CSR) components, and it is not something a small team should be building from scratch on a first-time submission deadline.

This guide is for the VP of Regulatory, the CMO, or the COO of an early-stage company who is looking at an IND filing on the horizon and wants to understand how outsourcing works, not in theory, but in practice. What do you hand off? When do you engage a partner? What does a good partner look like? What do you keep?

Step 1: Know What You’re Actually Outsourcing

You can’t outsource effectively if you’re not clear on what you’re handing off. And in regulatory, this is where a lot of early-stage teams get confused.

There are two distinct functions that often get lumped together under the umbrella of “regulatory.”

Regulatory Affairs (RA)

Encompasses strategy, agency relationships, labeling, scientific review, and the judgment calls about what goes into a submission. Your RA team, whether internal or contracted, owns this work. It requires deep knowledge of your compound, your clinical program, and FDA’s expectations for your specific indication and development stage.

Regulatory Operations (Reg Ops)

Sometimes called regulatory publishing or submission management, Reg Ops is responsible for the technical production and lifecycle management of the submission itself. This includes assembling the eCTD structure, managing sequence numbers, making granularity and leaf operation decisions, building and validating the XML backbone, running compliance checks, and managing the submission lifecycle from your first IND through every subsequent amendment, annual report, and safety update.

When you outsource regulatory submission management, you are primarily outsourcing the reg ops function. Your RA team continues to own strategy and content. The submission management partner owns the technical production and integrity of the submission package.

Step 2: Engage Earlier Than You Think You Need To

The single most common mistake early-stage teams make when outsourcing submission management is engaging a partner too late.

If your first IND target date is six months out, you should be in conversations with a submission management partner now. Not in three months. Not when you have a draft Module 2 ready. Now.

Here’s why early engagement matters:

• Your eCTD structure is established at sequence 0001 and you live with those decisions. The way your first submission is structured, how documents are broken down (granularity), how the XML backbone is organized, are decisions that create the foundation for every sequence that follows. Getting them right from the start prevents rework, reduces the risk of technical rejections, and makes lifecycle management significantly cleaner down the road.

• Pre-IND meeting preparation benefits from a reg ops perspective. A submission management partner who understands FDA’s technical expectations can help ensure that the documents you’re preparing for a pre-IND meeting are structured in a way that will translate cleanly into your IND filing.

• Onboarding takes time. A good submission partner will need to understand your compound, your development stage, your internal document workflows, and your team’s capacity. That knowledge-transfer takes time to do well.

• Technical rejections are almost always preventable and almost always the result of late starts. FDA issues technical rejections when submissions fail to meet eCTD format and content requirements. An experienced reg ops partner who is engaged early catches these issues before they reach the Agency.

Step 3: Know What to Look for in a Regulatory Submission Partner

Not all regulatory publishing vendors are the same. The market includes large global CROs with regulatory operations practices, niche eCTD publishing boutiques, staffing firms that place regulatory operations contractors, and purpose-built submission management firms. Evaluating them requires a clear framework.

Here are the criteria that matter most for early-stage companies:

FDA Experience

If your program is targeting US approval, you need a partner with deep, current FDA expertise. FDA’s eCTD specifications, technical requirements, and submission standards have their own nuances. A partner who works in the US regulatory environment every day will catch issues that a others may miss.

Ask:

• What percentage of the submissions your team manages are filed with FDA?

• What’s your team’s familiarity with current FDA eCTD guidance and the transition to eCTD 4.0?

Practitioner-Level Expertise, Not Account Management

There’s a meaningful difference between working with regulatory operations practitioners and working with account managers who manage relationships while the technical work happens elsewhere. For a first-time IND sponsor, you need direct access to the people who are actually building your submission.

Ask:

• Who will be doing the hands-on publishing work on my submission?

• Will I have direct access to that person?

• What is their background in regulatory operations?

Lifecycle Management Capability

Your IND is not a single event. It’s the beginning of a submission lifecycle that will include amendments, annual reports, safety updates, protocol modifications, and, if your program advances, eventually an NDA or BLA. A submission management partner understands lifecycle management and how decisions today impact future submissions.

eCTD Training as a Signal of Depth

Firms that offer eCTD training to client teams tend to understand the discipline at a fundamentally deeper level. Training requires you to articulate the why behind technical decisions, not just execute them. If a firm trains sponsor regulatory teams and product development teams on eCTD, it’s a reasonable signal that their practitioners understand the standards they’re working to, not just the tools they’re using.

Transparent, Documented Process

A qualified submission management partner should be able to walk you through their process from document receipt to completed, validated eCTD package ready for submission.

Ask:

• Ask for a process overview.

• Ask what happens when a document comes in that doesn’t meet their specifications.

• Ask how they communicate status and issues to your team.

Experience with Small Sponsors

Large CROs are built for large clients. Their processes, pricing structures, and engagement models are optimized for enterprise pharmaceutical companies with complex, high-volume submission programs. If you’re a lean early-stage team approaching your first IND, you need a partner who is sized and structured for your stage.

Ask:

• Ask about the size and stage of the clients they typically work with.

• Ask how they handle first-time sponsors who are going through the submission process for the first time.

WAYS has also published a white paper titled, The Key to Finding a Trusted Regulatory Submission Management Partner, which provides greater detail on this topic.

Step 4: Structure the Engagement Correctly

Once you’ve selected a partner, how you set up the engagement determines how well it works. Here’s what a well-structured outsourced submission management engagement looks like in practice:

• Define the scope clearly upfront. Which submissions are in scope? What is the target filing timeline? What deliverables is the partner responsible for and what deliverables is your team responsible for? Who is the primary point of contact on each side?

• Establish a document delivery process. Work with your partner to establish a document delivery schedule that gives them adequate time for intake, QC, and assembly. Don’t assume they can turn around a compliant submission in 48 hours if they receive documents the week before your filing window.

• Agree on QC checkpoints. Build in checkpoints where your RA team reviews the assembled submission before it’s finalized. Establish when those reviews happen, how feedback is communicated, and how long your team has to review.

• Align on what “submission-ready” means. Before you start, agree on exactly what the partner is delivering - a completed, validated eCTD package that passes FDA’s automated validation checks. Clarify who is responsible for final validation before the submission is dispatched.

• Build a communication cadence. Establish a regular check-in cadence that may increase in the weeks leading up to a filing, so that issues surface early and your partner has context about any changes or updates.

Step 5: Avoid the Most Common Outsourcing Mistakes

Even with the right partner and the right structure, early-stage teams make predictable mistakes when outsourcing submission management for the first time.

• Treating the publisher as a formatter. Regulatory publishing is not document formatting. Engage your partner on structural decisions, granularity, sequence planning, and document architecture, not just final assembly.

• Misaligning RA and reg ops. Your regulatory affairs team and your submission management partner need to be in communication. When those two functions aren’t aligned, you get last-minute changes that compress the publishing timeline and submission structures that don’t reflect your RA team’s strategy.

• Assuming one sequence is a one-time engagement. A partner who knows the history of your submission is significantly more efficient and less error-prone than starting fresh with each filing. Sequence continuity matters.

• Choosing on price alone. The cost difference between a high-quality submission management partner and a lower-quality alternative is trivial compared to the cost of a technical rejection, a program delay, or an agency hold that traces back to a submission error.

What Success Looks Like

A small US-based biotech has a promising small molecule in preclinical development. Their regulatory team is a single person, an experienced RA director who has worked at larger companies but has never been the person responsible for managing the mechanics of an eCTD submission. The company has no publishing infrastructure, no eCTD authoring tools, and a board that wants to see an IND filed within the year.

Rather than trying to hire a regulatory publisher, license an eCTD authoring platform, and build internal publishing capability from scratch, they engage a submission management partner six months before their IND target date.

The partner sets up the eCTD structure from the beginning. This activity helps define the document architecture and establish granularity standards. The RA director continues to own strategy, works directly with the CRO on study report authoring, and manages the FDA relationship. The submission partner handles everything technical: intake, QC, assembly, validation, and delivery of the completed eCTD package.

The IND is filed on time. No technical rejection. The RA director has direct access to the people doing the work. And when the first protocol amendment is needed six weeks later, the partner already knows the submission with no ramp-up, no re-explanation, just execution. That’s what a successful, outsourced submission management engagement looks like.

Starting Your Search

Outsourcing regulatory submission management is one of the most efficient decisions an early-stage pharma or biotech company can make, but only if it’s done intentionally, with the right partner, at the right time.

The short version: engage early, be clear about what you’re outsourcing (reg ops, not RA strategy), evaluate partners on FDA depth and practitioner expertise, and structure the engagement with clear scope, documented process, and aligned communication between your RA team and your reg ops partner.

If you’re approaching your first IND or planning a major filing and want to understand what outsourcing your submission management could look like for your program, we’d be glad to have that conversation.

WAYS Pharmaceutical Services specializes in eCTD submission management and regulatory publishing for pharmaceutical and biotechnology companies. Our team works frequently with US FDA submissions, with deep practitioner-level expertise in eCTD structure, lifecycle management, and submission strategy.

First IND submissions are high-stakes, and the outsourcing operational discussion shouldn’t take place under deadline pressure. WAYS helps sponsors just like you successfully file the first time, and every time. Reach out to our team today if you are ready to talk through your program and goals.